Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nelson N. Orie has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modulation of Redox Balance by Phytochemicals: Implications for Cardiovascular Health

    by Morana Jaganjac, Nelson N. Orie

    Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, with oxidative stress playing a major role in disease pathogenesis by promoting endothelial dysfunction, vascular inflammation, and tissue damage. Oxidative stress results from an imbalance between antioxidant defenses and reactive oxygen species (ROS) in favor of ROS. Excessive ROS damage macromolecules and may trigger a chain reaction of lipid peroxidation, protein modification, and DNA damage. Phytochemicals are naturally occurring compounds in fruits and vegetables that may modulate redox homeostasis and positively impact cardiovascular health. The flavonoid Quercetin, Resveratrol, Curcuminoids, Coenzyme Q10, Hydroxysafflor yellow A, and Vitamins C and E have shown promise in human studies for improving endothelial function, lipid profile and markers of oxidative stress and inflammation. Among the key mechanisms of protection are their antioxidant role, anti-inflammatory role or modulation of nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, all of which contribute to cardiovascular protection. However, there are challenges associated with their use for health, such as the complexity of their quality and quantity, which require standardization, as well as their mechanisms of effects. Moreover, their systemic availability and bioactivity largely depend on metabolic transformation by the host gut microbiota. This review analyzed relevant publications in PubMed, Scopus, and Web of Science, up to February 2026, and summarizes current knowledge on phyto–chemical-mediated modulation of oxidative stress and its implications for cardiovascular protection in humans. The evidence suggests that phytochemicals hold promise for CVD prevention and treatment, but more work is needed to achieve standardization in quality and quantity.


  • Open Access

    The Differential Modulatory Effects of Potassium Supplementation on Blood Pressure, Vascular Reactivity, Glomerular Filtration Rates, and Oxidative Stress in Different Experimental Hypertensive Models

    by Chukwuemeka R. Nwokocha, Javier Palacios, Melissa Kaydeen Reid, Nikolai Javier Nunes, Wesley Gray, Donovan McGrowder, Nelson N. Orie, Momoh A. Yakubu

    High-sodium/low-potassium in the modern diet, potassium excretion, and sodium retention have all been implicated in hypertension. Objectives: This study investigated the differential effects of potassium (K⁺) supplementation on blood pressure, renal function, and oxidative stress in two experimental hypertensive rat models: L-NAME-induced (nitric oxide synthase inhibitor-induced hypertension presenting with reduced NO bioavailability, endothelial dysfunction, vasoconstriction) and DOCA-salt-induced hypertension (deoxycorticosterone acetate + salt mimics volume-dependent hypertension of hypermineralocorticoidism, low renin, high sodium retention and severe cardiac fibrosis and oxidative stress). Methods: Male Sprague Dawley rats were treated with L-NAME or DOCA-salt, with or without 0.75% KCl dietary supplementation for eight weeks. Blood pressure, vascular reactivity, serum electrolytes, renal function markers, and malondialdehyde (MDA) levels were evaluated. Results: Potassium supplementation significantly reduced (20%) mean arterial pressure and (80%) oxidative stress markers in the L-NAME model but not in the DOCA-salt model. In both hypertensive models, K⁺ reduced (15%) vascular contractile response to phenylephrine, though it did not improve acetylcholine-induced vasodilation. Notably, K⁺ supplementation improved glomerular filtration rate (eGFR), sodium–potassium ratio, and renal biomarkers (urea and creatinine) in the L-NAME model, suggesting nephroprotection. However, in the DOCA-salt group, these markers either remained unchanged or worsened. Conclusions: These findings indicate that the antihypertensive and renoprotective effects of potassium are model-specific and depend on the underlying pathophysiological mechanisms, such as nitric oxide bioavailability and mineralocorticoid sensitivity. Dietary potassium may be more effective in patients with endothelial dysfunction-dominant hypertensive subtypes compared with volume-dependent hypertension and may call for K⁺ supplementation studies to be stratified by hypertension subtype.


  • Open Access

    Chronic reduction of store operated Ca2+ entry is viable therapeutically but is associated with cardiovascular complications

    by Fang Yu, Raphael Courjaret, Asha Elmi, Ethel Alcantara Adap, Nelson N. Orie, Fawzi Zghyer, Satanay Hubrack, Sajad Hayat, Nidal Asaad, Stefan Worgall, et al.

    Loss of function mutations in store-operated Ca2+ entry (SOCE) are associated with severe paediatric disorders in humans, including combined immunodeficiency, anaemia, thrombocytopenia, anhidrosis and muscle hypotonia. Given its central role in immune cell activation, SOCE has been a therapeutic target for autoimmune and inflammatory diseases. Treatment for such chronic diseases would require prolonged SOCE inhibition. It is, however, unclear whether chronic SOCE inhibition is viable therapeutically. Here we address this issue using a novel genetic mouse model (SOCE hypomorph) with deficient SOCE, nuclear factor of activated T cells activation, and T cell cytokine production. SOCE hypomorph mice develop and reproduce normally and do not display muscle weakness or overt anhidrosis. They do, however, develop cardiovascular complications, including hypertension and tachycardia, which we show are due to increased sympathetic autonomic nervous system activity and not cardiac or vascular smooth muscle autonomous defects. These results assert that chronic SOCE inhibition is viable therapeutically if the cardiovascular complications can be managed effectively clinically. They further establish the SOCE hypomorph line as a genetic model to define the therapeutic window of SOCE inhibition and dissect toxicities associated with chronic SOCE inhibition in a tissue-specific fashion.


  • Open Access

    Downregulation of CYP17A1 By 20-hydroxyecdysone: Plasma Progesterone and Its Vasodilatory Properties

    by Maneera Y Aljaber, Nelson N Orie, Asmaa Raees, Suhail Kraiem, Mashael Al-Jaber, Waseem Samsam, Mostafa M Hamza, David Abraham, Norman M Kneteman, Alka Beotra, et al.

    Aim: To investigate the effect of 20-hydroxyecdysone on steroidogenic pathway genes and plasma progesterone, and its potential impact on vascular functions. Methods: Chimeric mice with humanized li... Plain language summary The study looked at how the level of the hormone progesterone might be changed by taking a steroid called 20-hydroxyecdysone, which can be found in dietary supplements, and h... Graphical abstract


  • Open Access

    Untargeted Metabolomics Identifies a Novel Panel of Markers for Autologous Blood Transfusion

    by Amna Al-Nesf, Nada Mohamed-Ali, Vanessa Acquaah, Maneera Al-Jaber, Maryam Al-Nesf, Mohamed A. Yassin, Nelson N Orie, Sven Christian Voss, Costas Georgakopoulos, Rikesh Bhatt, et al.

    Untargeted metabolomics was used to analyze serum and urine samples for biomarkers of autologous blood transfusion (ABT). Red blood cell concentrates from donated blood were stored for 35–36 days prior to reinfusion into the donors. Participants were sampled at different time points post-donation and up to 7 days post-transfusion. Metabolomic profiling was performed using ACQUITY ultra performance liquid chromatography (UPLC), Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The markers of ABT were determined by principal component analysis and metabolites that had p < 0.05 and met ≥ 2-fold change from baseline were selected. A total of 11 serum and eight urinary metabolites, including two urinary plasticizer metabolites, were altered during the study. By the seventh day post-transfusion, the plasticizers had returned to baseline, while changes in nine other metabolites (seven serum and two urinary) remained. Five of these metabolites (serum inosine, guanosine and sphinganine and urinary isocitrate and erythronate) were upregulated, while serum glycourdeoxycholate, S-allylcysteine, 17-alphahydroxypregnenalone 3 and Glutamine conjugate of C6H10O2 (2)* were downregulated. This is the first study to identify a panel of metabolites, from serum and urine, as markers of ABT. Once independently validated, it could be universally adopted to detect ABT.